Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Back to Opinion

Drug Makers Buy Doctors

The story of how pharmaceutical firms buy doctors to prescribe given medication would be unbelievable if it appeared in some publication with less credibility than the Bulletin of the AARP.

Here’s the reported way in which a sales manager at Astra-Zeneca described the filthy operation: “There’s a big bucket of money sitting in every office. Every time you go in you reach your hand in the bucket and grab a handful.”

Little did the teller of this tale expect that his words would turn up on the Internet. But they did.

But even if they did not, the truth about the way in which pharmaceutical firms seek to buy doctors to prescribe their product would have been brought to public attention. A two-year Senate Finance Committee probe has concluded that by funding continuing medical education programs for doctors, pharmaceutical companies “have been able to increase their market for new products” and to illegally promote “off label uses” for their drugs. The committee has expressed concern that persuading doctors to use more costly drugs raises safety issues and most certainly places an additional cost on government funding.

The New England Journal of Medicine reports that 94% of doctors have a relationship with drug companies, 83% get free meals and 35% attend industry events.

They used to call such acts “bribery.” Now, we guess it goes under another name — like friendship.

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.

If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.

—  Rachel Fishman Feddersen, Publisher and CEO

With your support, we’ll be ready for whatever 2025 brings.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.